Searched for
INSULIN BIOSIMILAR PRODUCTS
Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billionBiocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as success...11 May, 2026, 09.00 AM IST- Biocon shifts focus to margins, capacity utilisation after expansion phaseBiocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in g...08 May, 2026, 10.19 PM IST
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...05 May, 2026, 05.35 PM IST
- Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-ShawBiocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate gr...21 Nov, 2025, 12.19 AM IST
- Biocon sees GLP-1 weight-loss therapy as a future growth driverBiocon will strengthen its insulin business while advancing in GLP-1 therapies, with semaglutide in Phase-III trials and a planned 2027 Ind...08 Aug, 2025, 09.42 PM IST
- Biocon Biologics gets USFDA nod for diabetes medicationBiocon Biologics has secured USFDA approval for Kirsty. Kirsty is an interchangeable biosimilar to NovoLog, used for diabetes treatment. It...16 Jul, 2025, 11.07 AM IST
- Biocon shares surge 3% as subsidiary obtains USFDA approval for diabetes drugBiocon share price jumped after its subsidiary Biocon Biologics received USFDA approval for Kirsty, a rapid-acting insulin biosimilar. This...16 Jul, 2025, 09.54 AM IST
- Biocon Biologics set to reap biosimilar insulin glargine opportunity in USDrugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and pr...22 Jan, 2022, 04.07 PM IST
- Biocon and Viatris to distribute Insulin Glargine through Walgreens in USWhile Viatris has commercialisation rights for the US, Canada, Australia, EU and others, Biocon will be able to commercialise the products ...19 Nov, 2021, 04.12 PM IST
- Biocon's interchangeable biosimilar Insulin glargine added on Express Scripts’ largest formulary in USThe listing is expected to boost Biocon's biosimilar business, as inclusion of Semglee on Express Scripts' NPF will allow pharmacies to sub...21 Oct, 2021, 10.30 AM IST
- Biocon Biologics interchangeable insulin Semglee gets US FDA approvalBiocon partnered with global healthcare company Viatris Inc to develop Semglee, the first interchangeable biosimilar product approved in th...30 Jul, 2021, 06.49 PM IST
- Biocon's partner firm launches diabetes product in JapanIn March this year, Biocon received approval from the Japanese health authority to sell its biosimilar product Insulin Glargine.15 Jul, 2016, 12.52 PM IST
- Biocon gets nod to sell its diabetes product 'Insulin Glargine' in JapanBiocon has received approval from the Japanese health authority to sell its biosimilar product 'Insulin Glargine' in that country.28 Mar, 2016, 04.08 PM IST
- Biocon targets emerging, developed markets with biosimilars"Biocon aims to provide high quality biosimilars to patients across the world, both in emerging and developed markets," Kiran Mazumdar-Shaw...22 Oct, 2015, 03.47 PM IST
- Biocon to focus on regional allies for commercialisationBiocon is altering its product commercialisation strategy by eyeing to partner with many regional players rather than joining hands with a ...29 Jul, 2012, 01.48 PM IST
- Biocon, Pfizer insulin deal called offBiotechnology giant Biocon has called off the deal with global pharma giant Pfizer to produce biosimilar versions of insulin and insulin an...13 Mar, 2012, 12.39 PM IST
- Biocon seals Rs 1,550 cr pact with PfizerThe agreement includes the commercialisation of Biocon’s biosimilar versions of insulin and insulin analog products: recombinant human insu...19 Oct, 2010, 12.26 AM IST
Load More
